MK-0616 has been shown to reduce levels of cholesterol by more than 60 per cent — depending on the dose. The Daily Mail
See also:
- Oral PCSK9 Inhibitor, MK-0616, Demonstrates Significant LDL-C Reduction in Phase 2b Trial Journal of the American College of Cardiology
No comments:
Post a Comment